secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunome Inc. (IMNM)
CIK:        0001472012
Form:       8-K
Filed at:   2024-02-13T23:59:59+00:00
Accession:  0001104659-24-019883
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunome announces $138.1M cash estimate, commences public offering; updates pipeline and AL102 acquisition
--------------------------------------------------------------------------------

- Preliminary cash, equivalents, and marketable securities of ~$138.1M as of Dec 31, 2023, subject to final close.
- Underwritten public offering of common stock commenced; proceeds intended to fund pipeline and operations.
- Signed asset purchase agreement with Ayala for AL102 (GSI) in desmoid tumors; expected close in late Q1 or early Q2 2024.
- Pipeline: IND filings for IM-1021 (ROR1 ADC), IM-4320 (anti-IL-38), and FAP RLT all targeted for Q1 2025.
- CEO Clay Siegall (former Seagen CEO) leads; management team includes former Morphimmune executives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472012/000110465924019883/0001104659-24-019883-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472012/000110465924019883/tm245878d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-019883

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer